共 11 条
[1]
Sacubitril–valsartan in heart failure and multimorbidity patients[J] . Raquel Rodil Fraile,Vincenzo Malafarina,Gregorio Tiberio López.ESC Heart Failure . 2018 (5)
[2]
Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction[J] . Kieran F. Docherty,John J.V. McMurray.International Journal of Cardiology . 2018
[3]
Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock[J] . H. A. Rawal,A. G. Kocheril,Tayfun Sahin.Case Reports in Cardiology . 2018
[4]
Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study[J] . Paola Beltrán,Patricia Palau,Eloy Domínguez,Mercedes Faraudo,Eduardo Nú?ez,Olga Guri,Anna Mollar,Juan Sanchis,Antoni Bayés-Genís,Julio Nú?ez.International Journal of Cardiology . 2018
[6]
Predictors of Death in Adults With Duchenne Muscular Dystrophy–Associated Cardiomyopathy[J] . Daniel Cheeran MD,Shaida Khan MD,Rohan Khera MD,Anish Bhatt MD,Sonia Garg MD,MEng,Justin L. Grodin MD,MPH,Robert Morlend MD,Faris G. Araj MD,Alpesh A. Amin MD,Jennifer T. Thibodeau MD,MSc,Sandeep Das MD,MPH,Mark H. Drazner MD,MSc,Pradeep P. A. Mammen MD.Journal of the American Heart Association . 2017 (10)
[8]
Cardiac Involvement Classification and Therapeutic Management in Patients with Duchenne Muscular Dystrophy[J] . Abdallah Fayssoil,Soumeth Abasse,Katy Silverston.Journal of Neuromuscular Diseases . 2017 (1)
[9]
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure[J] . John J.V. McMurray,Milton Packer,Akshay S. Desai,Jianjian Gong,Martin P. Lefkowitz,Adel R. Rizkala,Jean L. Rouleau,Victor C. Shi,Scott D. Solomon,Karl Swedberg,Michael R. Zile.The New England Journal of Medicine . 2014 (11)
[10]
Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy[J] . Hitoko Ogata,Yuka Ishikawa,Yukitoshi Ishikawa,Ryoji Minami.Journal of Cardiology . 2008 (1)